NEWS

Press Releases AND Media
In the News

Attralus Raises $25 Million to Transform Treatment for Patients with Systemic Amyloidosis

globalgenes.org
Source Author:

Rare Daily Staff

September 14, 2020
PDF Version
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

Attralus has launched with $25 million in a series A financing to diagnose and potentially reverse the underlying pathology of systemic amyloid diseases.

The financing, led by VenBio Partners, will allow Attralus to further validate its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain), and potentially ALECT2 systemic amyloidosis.

Attralus has launched with $25 million in a series A financing to diagnose and potentially reverse the underlying pathology of systemic amyloid diseases.

The financing, led by VenBio Partners, will allow Attralus to further validate its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain), and potentially ALECT2 systemic amyloidosis.

<< Back to All News

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.